CompletedNot Applicable

Retrospective Study in FFPE Samples From Younger Patients With Rhabdomyosarcoma

China6 participantsStarted 2023-04-01

Plain-language summary

This retrospective study is looking into mechanisms of drug therapy resistance in FFPE samples in recurrent and refractory Rhabdomyosarcoma (RMS) in pediatric patients who have experienced lung recurrence. The study employs advanced techniques such as single-cell transcriptomics and spatial transcriptomics to gain a comprehensive understanding of these mechanisms.

Who can participate

Age range1 Year – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Pediatric Patients: Participants in this study should be pediatric patients, typically defined as individuals aged from infancy to 18 years old, who have been diagnosed with recurrent and refractory Rhabdomyosarcoma (RMS).
✓. Lung Recurrence: Included patients must have a documented history of lung recurrence of RMS as a specific clinical manifestation.
✓. Availability of FFPE Samples: Patients for whom formalin-fixed paraffin-embedded (FFPE) tissue samples are available for analysis are eligible for inclusion.

Exclusion criteria

✕. Other Histological Types: Patients with RMS of histological subtypes other than those relevant to the study focus are excluded.
✕. Incomplete Clinical Data: Patients with incomplete or insufficient clinical data necessary for the study's objectives may be excluded to ensure robust analysis and interpretation of results.

What they're measuring

Gene expression pattern

Timeframe: 2023.12.31

Trial details

NCT IDNCT06040229

SponsorShandong First Medical University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-07-01

View on ClinicalTrials.gov More Alveolar Childhood Rhabdomyosarcoma trials